巴西6月龄至4岁儿童COVID-19疫苗系列对重症的保护效果:基于人群的队列研究(2023-2024)
该研究在巴西24个市开展回顾性队列研究,评估BNT162b2三剂系列在6月龄至4岁儿童及CoronaVac两剂系列在3至4岁儿童中减少COVID-19相关SARI住院的效果。结果显示BNT162b2三剂系列有效性为97%(IRR 0.03,95%CI 0.01-0.10),而CoronaVac有效性小且无统计学意义(IRR 0.96,95%CI 0.57-1.62)。
要点
- BNT162b2三剂系列在6月龄至4岁儿童中减少COVID-19相关SARI住院的有效性达97%。
- CoronaVac两剂系列在3至4岁儿童中的有效性小且无统计学意义。
- 完成BNT162b2基础系列与COVID-19相关SARI住院率显著降低相关。
核心结论
- 完成BNT162b2三剂基础系列与6月龄至4岁儿童COVID-19相关SARI住院率显著降低相关。
研究设计与样本
- 巴西24个市的回顾性队列研究,使用监测数据,随访37.7百万人月,纳入1384例COVID-19相关SARI住院和27例相关死亡。
主要发现
- BNT162b2三剂系列在6月龄至4岁组有效性97%(IRR 0.03,95%CI 0.01-0.10),各年龄亚组估计无显著差异。
- CoronaVac在3至4岁儿童中有效性小且无统计学意义(IRR 0.96,95%CI 0.57-1.62)。
关键数值与推荐
- BNT162b2三剂系列有效性97%(IRR 0.03,95%CI 0.01-0.10)。
- CoronaVac两剂系列IRR 0.96(95%CI 0.57-1.62)。
临床怎么用
- 在6月龄至4岁儿童中,完成BNT162b2三剂基础系列可显著降低COVID-19相关SARI住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the impact of COVID-19 vaccination is widely documented in the general population, the evidence on its effectiveness in children under 5 years of age is still limited. In this context, the continuation of vaccination programs in this age group has been debated globally. Consequently, we estimated the effectiveness of the complete 3-dose series of BNT162b2 (Pfizer-BioNTech) in children aged 6 months to 4 years and the complete 2-dose series of CoronaVac (Sinovac) in children aged 3 to 4 in reducing the risk of hospitalizations due to COVID-19-attributed severe acute respiratory infection (SARI) in Brazil. METHODS: We conducted a retrospective cohort study in 24 Brazilian municipalities, using surveillance data. We evaluated vaccine effectiveness in reducing the incidence rate of COVID-19-attributed SARI hospitalizations from July 2023 to December 2024. Covariate adjustments, defined a priori based on a conceptual model, were implemented using random-effects Poisson regression models. RESULTS: The cohort comprised 37.7 million person-months of follow-up and 1384 COVID-19-attributed SARI hospitalizations, including 27 associated deaths. The 3-dose series of BNT162b2 vaccine had an effectiveness of 97% (Incidence rate ratio [IRR] 0.03, 95% CI 0.01-0.10) in the group aged 6 months to 4 years, with no significant differences among age-specific estimates. The effectiveness of CoronaVac was small and not statistically significant (IRR 0.96, 95% CI 0.57-1.62). CONCLUSIONS: In this population-based cohort, completion of the 3-dose BNT162b2 primary series was associated with substantially lower rates of COVID-19-attributed SARI among children aged 6 months to 4 years.
引用
- Schrarstzhaupt IN, Diaz-Quijano FA. Effectiveness of COVID-19 vaccination schedules against severe COVID-19 in children aged 6 months to 4 years in Brazil: A population-based cohort study (2023-2024). Vaccine. 2026. PMID: 42664527. doi:10.1016/j.vaccine.2026.129096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。